Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta surges as investors cheer expanded use of gene therapy
06:53am, Friday, 21'st Jun 2024
Sarepta Therapeutics shares surged about 36% in premarket trading on Friday as an expanded use approval opened up a bigger market in the U.S. for its gene therapy for patients with Duchenne muscular d
Why has the Sarepta stock price (SRPT) gone up more than 35%?
05:12am, Friday, 21'st Jun 2024
Sarepta Therapeutics (NASDAQ: SRPT), a pharmaceutical company that describes itself as specializing in “precision genetic medicine for rare diseases”, saw its stock price shoot up by 36% in after-
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
08:30pm, Thursday, 20'th Jun 2024
Sarepta rocketed late Thursday after the FDA approved its Duchenne muscular dystrophy gene therapy for all patients age 4 and older.
Sarepta Therapeutics receives expanded approval for Elevidys
07:41pm, Thursday, 20'th Jun 2024
Sarepta Therapeutics Inc (NASDAQ: SRPT) rallied a whopping 40% in extended hours today following a key announcement from the U.S. Food and Drug Administration regarding Elevidys. Elevidys is the com
US FDA approves expanded use of Sarepta's Duchenne gene therapy
05:43pm, Thursday, 20'th Jun 2024
The U.S. Food and Drug Administration allowed the expanded use of Sarepta Therapeutics' gene therapy for all patients with Duchenne muscular dystrophy aged four and above on Thursday.
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
05:02pm, Thursday, 20'th Jun 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics announces the expanded U.S. FDA approval of ELEVIDYS to Duchenne muscular dystrophy patients ages 4 and above.
Sarepta Therapeutics: Navigating Elevidys Upside Potential
01:29pm, Monday, 17'th Jun 2024
Sarepta Therapeutics submitted a request to the FDA for label expansion of Elevidys, with a response expected by June 21st. Roche initiated the process for Elevidys marketing authorization application
Pfizer's gene-therapy trial failure boosts Sarepta's stock
08:49am, Thursday, 13'th Jun 2024
Shares of Sarepta Therapeutics Inc. SRPT, -1.15% gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial.
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
07:00am, Thursday, 06'th Jun 2024
If a portfolio is passively managed, investors tend to buy and forget. This however holds true for high-quality blue-chip and growth stocks.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:45pm, Friday, 31'st May 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2024 (the “Grant Date”) th
Sarepta Therapeutics stock to enter S&P MidCap 400: Should you buy?
08:07am, Thursday, 30'th May 2024
Sarepta Therapeutics (NASDAQ:SRPT) is set to make a significant move by entering the S&P MidCap 400 index, replacing Shockwave Medical. This change, effective before trading begins on June 3, 2024, fo
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
12:00pm, Saturday, 04'th May 2024
Biotechnology offers breakthrough drugs and treatments that open new doors in the field of medicine. Companies are releasing more drugs and developing state-of-the-art methods to treat previously untr
Gene Therapy Pioneer Jerry R. Mendell, M.D.
10:07am, Friday, 03'rd May 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
12:16pm, Thursday, 02'nd May 2024
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
08:36pm, Wednesday, 01'st May 2024
Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with
